Symptomatic interferon retinopathy successfully treated by hypertension management.
Han
C
C
O'Day
J
J
D000959:Antihypertensive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000150:complications*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced*
D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Am J Ophthalmol. 2001 Jun;131(6):782-7
11384576
Liver. 2001 Jun;21(3):192-7
11422782
J Hepatol. 2006 Jan;44(1):56-61
16223542
Arch Ophthalmol. 1993 Mar;111(3):350-6
8447745
Am J Gastroenterol. 1996 Feb;91(2):309-13
8607498
J Immunol. 2004 Feb 1;172(3):1699-710
14734752